Sulfonylurea Class of Antidiabetic Drugs Inhibit Acetylcholinesterase Activity: Unexplored Auxiliary Pharmacological Benefit toward Alzheimer's Disease.
Journal
ACS pharmacology & translational science
ISSN: 2575-9108
Titre abrégé: ACS Pharmacol Transl Sci
Pays: United States
ID NLM: 101721411
Informations de publication
Date de publication:
12 Feb 2021
12 Feb 2021
Historique:
received:
13
10
2020
entrez:
22
2
2021
pubmed:
23
2
2021
medline:
23
2
2021
Statut:
epublish
Résumé
Contemporary literature documents extensive research on common causative mechanisms, pathogenic pathways and dual effective remedies for Alzheimer's disease (AD) and Type 2 diabetes mellitus (T2DM). Tolbutamide (TBM), chlorpropamide (CPM), and glyburide (GLY) are three sulfonylurea antidiabetic drugs of different generations. All these drugs were found to exhibit moderate to strong inhibitory efficiency on the neurotransmitter degrading enzyme acetylcholinesterase (AChE) with GLY (IC
Identifiants
pubmed: 33615172
doi: 10.1021/acsptsci.0c00168
pmc: PMC7887854
doi:
Types de publication
Journal Article
Langues
eng
Pagination
193-205Informations de copyright
© 2021 American Chemical Society.
Déclaration de conflit d'intérêts
The authors declare no competing financial interest.
Références
Neurology. 2008 Sep 30;71(14):1065-71
pubmed: 18401020
Neurol India. 2000 Dec;48(4):308-13
pubmed: 11146591
Anaesthesia. 2009 Mar;64 Suppl 1:1-9
pubmed: 19222426
Alzheimers Dement. 2017 Jan;13(1):1-7
pubmed: 27583652
Spectrochim Acta A Mol Biomol Spectrosc. 2016 Jan 5;152:23-33
pubmed: 26186394
Am J Epidemiol. 2001 Oct 1;154(7):635-41
pubmed: 11581097
J Alzheimers Dis. 2005 Dec;8(3):247-68
pubmed: 16340083
Biochem Pharmacol. 1961 Jul;7:88-95
pubmed: 13726518
Biochem Biophys Res Commun. 2011 Jan 28;404(4):935-40
pubmed: 21185266
Ther Adv Neurol Disord. 2013 Jan;6(1):19-33
pubmed: 23277790
Mayo Clin Proc. 2009;84(1):28-33
pubmed: 19121251
Br Med J. 1978 Jan 21;1(6106):142-4
pubmed: 620227
PLoS One. 2015 Apr 13;10(4):e0121092
pubmed: 25874456
Behav Brain Res. 2008 Jun 3;189(2):381-6
pubmed: 18336929
CNS Neurol Disord Drug Targets. 2014 Apr;13(3):447-51
pubmed: 24059302
J R Soc Interface. 2015 Jan 6;12(102):20140891
pubmed: 25392397
Neurobiol Aging. 2006 Feb;27(2):190-8
pubmed: 16399206
Neurochem Res. 2016 Jun;41(6):1475-82
pubmed: 26886763
J Comput Chem. 2010 Mar;31(4):671-90
pubmed: 19575467
Sci Rep. 2017 Jun 12;7(1):3219
pubmed: 28607438
J Med Chem. 2006 Oct 19;49(21):6177-96
pubmed: 17034125
ACS Nano. 2017 Mar 28;11(3):2313-2381
pubmed: 28290206
J Biomol Struct Dyn. 2015;33(5):1107-25
pubmed: 24905476
Arch Med Sci. 2015 Aug 12;11(4):840-8
pubmed: 26322096
Chem Rev. 2009 Sep;109(9):4025-53
pubmed: 19572643
J Alzheimers Dis. 2005 Feb;7(1):63-80
pubmed: 15750215
J Med Chem. 2018 Sep 13;61(17):7630-7639
pubmed: 30125110
J Biol Chem. 2012 Mar 16;287(12):9299-310
pubmed: 22275369
Metabolism. 1980 May;29(5):488-94
pubmed: 6990184
J Cell Biochem. 2017 Nov;118(11):3855-3865
pubmed: 28387957
J Biomol Struct Dyn. 2019 Feb;37(2):321-335
pubmed: 29320928
Curr Neuropharmacol. 2013 May;11(3):315-35
pubmed: 24179466
Exp Gerontol. 2012 Nov;47(11):858-64
pubmed: 22884853
Nat Clin Pract Neurol. 2006 Mar;2(3):159-66
pubmed: 16932542
Oxid Med Cell Longev. 2017;2017:7303096
pubmed: 28770024
Biotechnol Appl Biochem. 2016 Jan-Feb;63(1):145-50
pubmed: 25402624
Neurosci Biobehav Rev. 2011 May;35(6):1397-409
pubmed: 21392524
Prog Neurobiol. 2015 Jun;129:37-57
pubmed: 25857551
Pharmacol Rep. 2016 Feb;68(1):127-38
pubmed: 26721364
ACS Chem Neurosci. 2014 May 21;5(5):377-89
pubmed: 24628027
Ann N Y Acad Sci. 1959 Mar 30;74(3):473-7
pubmed: 13637585
Mol Pharm. 2018 Jun 4;15(6):2206-2223
pubmed: 29745222
J Chem Phys. 2007 Jan 7;126(1):014101
pubmed: 17212484
Altern Med Rev. 2009 Dec;14(4):373-9
pubmed: 20030463
J Comput Chem. 2013 Sep 30;34(25):2135-45
pubmed: 23832629